Michael Recht

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3738641/publications.pdf

Version: 2024-02-01

40	3,364	567281 15	302126 39
papers	citations	h-index	g-index

40	40	40	3010
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Incorporating the patient voice and patient engagement in GOALâ€HÄ“m: Advancing patientâ€centric hemophilia care. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12655.	2.3	5
2	Resource utilization and treatment costs of patients with severe hemophilia A: Realâ€world data from the ATHNdataset. EJHaem, 2022, 3, 341-352.	1.0	4
3	Building the blueprint: Formulating a communityâ€generated national plan for future research in inherited bleeding disorders. Haemophilia, 2022, 28, 760-768.	2.1	10
4	The GOALâ€HÄ“m journey: Shared decision making and patientâ€centred outcomes. Haemophilia, 2022, 28, 784-795.	2.1	4
5	Results of genetic analysis of 11â€‰341 participants enrolled in the My Life, Our Future hemophilia genotyping initiative in the United States. Journal of Thrombosis and Haemostasis, 2022, 20, 2022-2034.	3.8	10
6	Management of inhibitors in persons with nonâ€severe hemophilia <scp>A</scp> in the <scp>United States</scp>. American Journal of Hematology, 2021, 96, E9-E11.	4.1	4
7	Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B. Blood Advances, 2021, 5, 2732-2739.	5.2	11
8	Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model. Journal of Medical Economics, 2021, 24, 363-372.	2.1	8
9	A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE). Journal of Blood Medicine, 2021, Volume 12, 883-896.	1.7	3
10	A Delphi Consensus Approach for Difficult-to-Treat Patients with Severe Hemophilia A without Inhibitors. Journal of Blood Medicine, 2021, Volume 12, 913-928.	1.7	1
11	Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations. Value in Health, 2021, 24, 1628-1633.	0.3	11
12	Safety first: Tracking adverse events associated with new therapies for people with hemophilia. Journal of Thrombosis and Haemostasis, 2021, 19, 3-5.	3.8	1
13	Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders. Journal of Blood Medicine, 2021, Volume 12, 897-911.	1.7	21
14	Inhibitors and mortality in persons with nonsevere hemophilia A in the United States. Blood Advances, 2020, 4, 4739-4747.	5.2	4
15	Hemophilia without prophylaxis: Assessment of joint range of motion and factor activity. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1035-1045.	2.3	3
16	The impact of extended halfâ€life factor concentrates on prophylaxis for severe hemophilia in the United States. American Journal of Hematology, 2020, 95, 960-965.	4.1	19
17	Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. Blood Advances, 2020, 4, 2451-2459.	5.2	67
18	The national blueprint for 21st century data and specimen collection and observational cohort studies: NHLBI State of the Science Workshop on factor VIII inhibitors. Haemophilia, 2019, 25, 590-594.	2.1	6

#	Article	IF	Citations
19	Healthâ€related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, nonâ€interventional study (NIS). Haemophilia, 2019, 25, 382-391.	2.1	28
20	Why plasmaâ€derived factor VIII?. Haemophilia, 2019, 25, e183-e185.	2.1	0
21	Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Advances, 2019, 3, 3241-3247.	5.2	85
22	Delirium in the pediatric hematology, oncology, and bone marrow transplant population. Pediatric Blood and Cancer, 2019, 66, e27640.	1.5	15
23	Community counts: Evolution of a national surveillance system for bleeding disorders. American Journal of Hematology, 2018, 93, E137-E140.	4.1	15
24	Patientâ€reported outcomes and joint status across subgroups of <scp>US</scp> adults with hemophilia with varying characteristics: Results from the Pain, Functional Impairment, and Quality of Life (Pâ€FiQ) study. European Journal of Haematology, 2018, 100, 14-24.	2.2	10
25	Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patientâ€reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (Pâ€FiQ) study. European Journal of Haematology, 2018, 100, 5-13.	2.2	37
26	Pilot study of novel lab methodology and testing of platelet function in adolescent women with heavy menstrual bleeding. Pediatric Research, 2018, 83, 693-701.	2.3	3
27	Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry. American Journal of Hematology, 2017, 92, 646-652.	4.1	10
28	Management of <scp>US</scp> men, women, and children with hemophilia and methods and demographics of the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (Bâ€<scp>HERO</scp>â€S) study. European Journal of Haematology, 2017, 98, 5-17.	2.2	25
29	Reliability of patient-reported outcome instruments in US adults with hemophilia: the Pain, Functional Impairment and Quality of life (P-FiQ) study. Patient Preference and Adherence, 2017, Volume 11, 1603-1612.	1.8	15
30	Construct validity of patient-reported outcome instruments in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Patient Preference and Adherence, 2017, Volume 11, 1369-1380.	1.8	20
31	Epistaxis as a Common Presenting Symptom of Glanzmannâ€™s Thrombasthenia, a Rare Qualitative Platelet Disorder: Illustrative Case Examples. Case Reports in Emergency Medicine, 2017, 2017, 1-6.	0.3	6
32	Fatal carboplatin-induced immune hemolytic anemia in a child with a brain tumor. Journal of Blood Medicine, 2014, 5, 55.	1.7	9
33	Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B. New England Journal of Medicine, 2014, 371, 1994-2004.	27.0	1,063
34	Impact of Acute Bleeding on Daily Activities of Patients with Congenital Hemophilia with Inhibitors and Their Caregivers and Families: Observations from the Dosing Observational Study in Hemophilia (DOSE). Value in Health, 2014, 17, 744-748.	0.3	20
35	Long-Term Orthopedic Effects Of Delaying Prophylaxis In Severe Hemophilia A Until Age 6 Years: Results Of The Joint Outcome Study Continuation (JOSc). Blood, 2013, 122, 210-210.	1.4	4
36	Effect of Acute Bleeding on Daily Quality of Life Assessments in Patients with Congenital Hemophilia with Inhibitors and Their Families: Observations from the Dosing Observational Study in Hemophilia. Value in Health, 2012, 15, 916-925.	0.3	47

#	Article	IF	Citations
37	Current Options and New Developments in the Treatment of Haemophilia. Drugs, 2011, 71, 305-320.	10.9	34
38	Thrombocytopenia and Anemia in Infants and Children. Emergency Medicine Clinics of North America, 2009, 27, 505-523.	1.2	7
39	Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia. New England Journal of Medicine, 2007, 357, 535-544.	27.0	1,681
40	Differences in Platelet Î±-granule Release between Normals and Immune Thrombocytopenic Patients and between Young and Old Platelets. Thrombosis and Haemostasis, 1998, 80, 457-462.	3.4	38